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S202 Poster Session Ichildren’s parents. Unlike public banks, which utilize specific criteria
for banking, private banks generally store any collected unit regard-
less of size or cell content.
Methods: Patients with neurological disorders with banked aCB
were self-referred or referred by their treating physicians. CB
units (CBU) containing .110e7 cells/kg were shipped to Duke
from the banks of origin after confirming identity by HLA typing.
Viability was confirmed on a test sample when available. CBUs,
50% stored in bags and 50% in vials, were thawed and washed
in the standard fashion. Patients were premedicated with Tylenol,
Benadryl and Solumedrol prior to infusion and monitored for
4 hours. Data about patients, infusions and CBUs were collected
retrospectively. Characteristics of CBUs were compared to exist-
ing data from CBUs publicly banked at the Carolinas Cord Blood
Bank.
Results:From 3/2004 to 8/2009, 154 children with neurological dis-
orders (78% cerebral palsy, 13% congenital hydrocephalus, 9%
other injuries) received 164 aCB infusions. Median age at infusion
was 2 yrs (range 6 days–9 yrs). One patient had an anaphylactic infu-
sion reaction which responded to medical therapy and stopping the
infusion. Mean pre-cryopreservation volume (66.2 vs 97.6 ml,
p\0.001), TNC (12.3 vs 15.510e8, p\0.001), and CD34 (3.0
vs 4.110e6, p5 0.004) were significantly lower than publicly stored
CBUs. Post thaw sterility cultures were positive in 6.5% of CBUs in-
fused versus 0.5% of publicly stored units. Post thaw recoveries of
TNC, 3.310e8 (27% pre-cryo TNC), and CD34, 1.2 (40% pre-
cryo CD34), were also lower than expected.
Conclusions: IV infusion of aCB is safe and feasible in young chil-
dren with neurological conditions. The overall quality parameters of
privately banked UCBs was inferior to those stored in public banks.
If evidence for efficacy of aCB is established clinically, the quality of
aCB units should be held to the same standards as those stored in
public banks.120
TREATMENT WITH HYPER-CVAD RESULTS IN POOR MOBILIZATION OF
PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH MANTLE CELL
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Background: Hyper-CVAD (fractionated cyclophosphamide, vin-
cristine, doxorubicin and dexamethasone combined with high
doses of cytarabine and methotrexate) is an intense chemotherapy
regimen frequently used as front line therapy for a number of he-
matologic malignancies including mantle cell lymphoma. It has
been observed anecdotally that patients with mantle cell lym-
phoma who have been treated with hyper-CVAD have more dif-
ficulty mobilizing sufficient PBSC than those who have been
treated with alternative regimens.
Patients and Methods: To address this question, we retrospec-
tively analyzed mobilization data from 74 consecutive patients
over the age of 18 diagnosed with mantle cell lymphoma who un-
derwent ASCT at the Cleveland Clinic between July, 1996 and
November, 2008. 26 of these patients had previously been treated
with hyper-CVAD and 48 had received alternative regimens (pre-
dominantly CHOP with or without rituximab). Patients treated
with hyper-CVAD were more likely to have undergone mobiliza-
tion with VP16 + G-CSF (VP-G): 92% received VP-G, whereas
only 50% of patients treated with alternative regimens received
VP-G (P5\ 0.001).
Results: Patients treated with hyper-CVAD collected fewer CD34+
stem cells on day 1 (median5 0.43 106 CD34+ cells/kg) compared
to patients treated with alternative regimens (median5 3.00  106,
P5 0.002, see Table). In addition, patients treated with hyper-
CVAD were also more likely to fail in collecting sufficient CD34+
cells during their first mobilization attempt compared to patients
treated with alternative regimens 23.1% vs. 4.2%, P5 0.012). Pa-tients treated with hyper-CVAD underwent a median total of 5
days of pheresis vs. 3 days for patients treated with alternative regi-
mens (P5 0.019).
Conclusions: Compared to patients treated with alternative regi-
mens, patients with mantle cell lymphoma treated with hyper-
CVAD were more likely to undergo mobilization with a VP16-con-
taining regimen yet still collected fewer CD34+ cells (day 1, day 2,
days 1 + 2, and total), required more total days of pheresis, and
more frequently required a second mobilization attempt. These re-
sults suggest a potential role of alternative mobilizing strategies in
patients with mantle cell lymphoma as an adjuvant to standard prim-
ing regimens in order to improve mobilization of PBSC prior to
ASCT.
Table. Mobilization Results
Hyper-CVAD (N5 26) Alternative Regimens (N5 48)CharacteristicMedian
(range) (Number
percent)Median
(range)Number
(percent) PCD341 cells
collected on
day 1 (x 106/kg)0.43
(0.09-13.33)3.00
(0.02-60.36)0.002CD341 cells
collected on day
2 (x 106/kg)0.62
(0.09-12.88)2.65
(0.11-29.16)0.008Total CD341 cells
collected
(x 106/kg)4.13
(2.11-27.88)8.92
(2.06-89.52)0.037Total days of
pheresis5 (2-11) 3 (2-10) 0.019Number of
patients who
failed to collect
sufficient CD341
cells during first
mobilization
attempt6 (23.1%) 2 (4.2%) 0.012121
CYCLOPHOSPHAMIDE OR PLERIXAFOR AND G-CSF STEM CELL MOBILI-
ZATION (SCM): INITIAL COST COMPARISON ANALYSIS
Jagasia,M.H.1, Pickard, S.2, Chen, H.3, Dixon, S.4, Savani, B.N.5 1Van-
derbilt University Medical Center, Nashville, TN; 2University of Illinois,
Chicago, IL; 3Vanderbilt University Medical Center, Nashville, TN
Objectives: Autologous SCM is usually done using myelosuppres-
sive chemotherapy plus G-CSF (G), which is considered safe and ef-
fective, but exposes patients (pts) to risks and side effects. To better
understand the comparative effectiveness of standard and newer
treatments for SCM, the aims of study were: (1) clinical outcomes
and cost consequences of cyclophophamide (CY) plus G SCM (2)
to compare outcomes of CY + G to a clinical trial of plerixafor
(P)+G.
Methods: A retrospective study was conducted in all patients un-
dergoing first SCM from 1/04 to 3/08 (N5 241) with CY (3
gm/m2) and G (10 mcg/kg started day after CY for 10 days with
a planned first day of collection on day 11) and pheresis initiated
when peripheral blood had .15 CD34+ cells/uL. Positive clinical
outcome (PCO) was defined as .2106 CD34+ cells/kg collected
on planned day of collection in 1 or 2 apheresis without a prior
negative event that led to additional clinic/inpatient evaluation.
The cost of drugs, pheresis, product processing, and clinical events,
were reported based on Medicare part B physician, laboratory, and
ancillary fee schedule. Data on pts undergoing SCM with P + G
were obtained from a published clinical trial in pts with myeloma
Poster Session I S203(MM) and lymphoma (L) undergoing first SCM that used G (10
mcg/kg without dose escalation) and non-mobilizers had a maxi-
mum of 4 days of P.
Results: Among CY + G pts, 141 (61%) were males; 121 (50%) had
MM, 115 (48%) had L (5-other diagnoses); 61 (25%) pts. had prior
radiation. PCO was seen in 48 (20%) pts., 23% of MM and 15.7% of
L pts. Mean total cost of CY + G SCM was $10,732 (range, 6988-
30827). PCO was associated with a lower cost than non-PCO in
the overall group, (mean, $10,371 vs. $12,870, P5 0.001), in MM
pts. (mean, $10,511 vs. $12,152, P5 0.026), and in L pts (mean,
$10,133 vs. $13,627, P5 0.006). Assuming a similar distribution of
PCO in 100 pt. with MM and L, the projected per pt cost of SCM
would be $11,774 and $13,067 (mean, $12,421) with CY + G. Pro-
jected costs of SCM using P + G for 100 pts. with MM and L were
$12,852 and $8986 (mean, $10,919).
Conclusion: SCM with CY + G was associated with a lower rate of
PCO and higher cost than P + G. This comparision is limited by dif-
ferent sources of patient data, only the CY + G data was ‘‘real world’’,
and only product-related costs were examined. This study represents
an important initial step towards informing cancer management
based on a profile of outcomes that compare relevant therapeutic al-
ternatives.122
PLERIXAFOR PLUS G-CSF RESULTED IN SIMILAR COST BUT MORE PRE-
DICTABLE DAYS OF APHERESIS COMPARED TO CHEMOTHERAPY PLUS G-
CSF FOR MOBILIZATION OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS
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Plerixafor plus G-CSF has been shown to mobilize more
CD34+ cells than G-CSF alone for autologous hematopoietic
stem cell transplant (HSCT). However, many centers use chemo-
therapy (chemo) followed by G-CSF to mobilize CD34+ cells
prior to HSCT. We performed a retrospective study of pts
who participated in the expanded access program (EAP) of pler-
ixafor/G-CSF for upfront mobilization of CD34+ cells, and com-
pared outcomes to matched historical controls mobilized with
chemo/G-CSF at two centers that participated in the study. Con-
trol pts were matched for age, sex, disease stage, and number of
prior therapies. Control pts received cyclophosphamide 3-5 gm/
m2 followed by daily G-CSF. Study pts received G-CSF 10
mcg/kg daily for 5 days and plerixafor 0.24 mg/kg was given
on the evening of day 4, twelve hours before apheresis on day
5. Mobilization costs were considered to be the costs of medical
procedures, resource utilization and medications. Median national
CMS reimbursement rates were used to evaluate the costs of pro-
cedures, hospitalization, provider visits, apheresis, CD34+ cell
processing and cryopreservation. Average sale price was used
for G-CSF, plerixafor, cyclophosphamide, mesna, antiemetics
and antimicrobials. A total of 34 patients from EAP and 34
matched controls were studied. Comparison of the number of
doses of G-CSF, number of apheresis, total CD34+ cells col-
lected, and cost is given in the table. Two pts in the control
group were hospitalized for neutropenic fever during the mobili-
zation period after receiving chemo. Apheresis started on the
scheduled day in 27 (79%) study pts and in 18 (53%) control
pts (p5 0.021). Unplanned starts of apheresis resulted in 17
(50%) control pts undergoing weekend apheresis. Study pts re-
ceived a median of 1 dose of plerixafor (median 16.9 mg), and
the average sale price for plerixafor in this analysis was $6,250
per 24 mg/vial. All pts proceeded to HSCT with no difference
in outcomes. In conclusion, plerixafor/G-CSF compared to
chemo/G-CSF for upfront mobilization of CD34+ cells resulted
in similar number of cells collected, cost of mobilization, and
clinical outcomes. However, plerixafor/G-CSF mobilization re-
sulted in more predictable days of collection, no weekend apher-esis procedures, and no unscheduled hospital admissions. Higher
acquisition cost of plerixafor was offset by less G-CSF use and
less resource utilization compared to cyclophosphamide based
mobilization.
Cost and Resource Comparison
All values median(range) Plerixafor/GCSF Chemo/GCSF p valueG-CSF dose 780ug (600-1440) 900ug (480-1260) 0.9No. G-CSF doses 5 (4-8) 10 (6-17) 0.0001Apheresis days 1 (1-4) 1 (1-4) 0.33Total CD34 cells
(million/kg)11.1 (3.5-37.9) 11.2 (2.1-69.3) 0.86Un-scheduled
hospital days0 2 0.0001Weekend
apheresis0 17 (50%) 0.0001Total Mobilization
Cost$18,817
(12,467-53,799)$18,893
(10,196-35,088)0.35123
EFFICACY OF PLERIXAFOR PLUS G-CSF IN HEMATOPOIETIC STEM CELL
(HSC) REMOBILIZATION IN PATIENTS WITH AMYLOIDOSIS
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Introduction: High-dose melphalan and autologous HSC trans-
plantation produces the highest remission rate for patients (pts)
with amyloidosis. HSC mobilization/collection is challenging in
these patients, particularly those with cardiac involvement with re-
ported increased morbidity and even mortality. Thus, agents that
can mobilize stem cells safely, efficiently and effectively would be
beneficial in these patients. This retrospective analysis evaluated
the efficacy and safety of plerixafor + G-CSF (P + G) remobilization
in amyloidosis pts.
Methods: Pts with amyloidosis unable to collect $2106 CD34+
cells/kg in prior attempts were remobilized with P + G in a compas-
sionate use program (CUP). G-CSF (10 mg/kg SC) was given every
morning for 5 days. Plerixafor (0.24 mg/kg SC) was given in the
evening on Day 4,11 hours prior to apheresis the next day. Plerix-
afor, G-CSF and apheresis were repeated daily until pts collected
$2106 cells/kg.
Results: Of 1011 pts in the plerixafor CUP database, 11 pts were re-
ported to have amyloidosis. In prior mobilization attempts, 3 pts col-
lected 0.8, 0.17 and 0.9106 CD34+ cells/kg and in 8 pts, collection
was not attempted due to low circulating peripheral blood CD34+
cell numbers. Remobilization with P + G resulted in a median yield
of 6.6106 cells/kg; 10/11 pts collected the minimum target of
2106 cells/kg and 7/11 pts reached the optimal target of $5106
cells/kg with the majority (10/11) collecting the minimum cell
dose in 1 or 2 apheresis days. Ten pts went to transplant; median
time to platelet and neutrophil engraftment was 19 and 14 days, re-
spectively. Drug-related adverse events were experienced by 5 pts
during mobilization and collection and included injection site reac-
tions (5), nausea (2), diarrhea (2), headache (1), hyperuricemia (1),
hypokalemia (1), paraesthesias (1) and QT prolongation on electro-
cardiogram (1). The patient with the prolonged QT interval had car-
diac amyloidosis and hypokalaemia. This patient died approximately
1 month after mobilization and collection, of cardiac arrest not re-
lated to plerixafor.
Conclusion: These results provide preliminary evidence that P + G
can safely and effectively remobilize HSC in amyloidosis pts who
